MindBio Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Selling, General & Admin	0.43	0.63	1.82	2.9
Research & Development	-	-	-	2.46
Amortization of Goodwill & Intangibles	-	-	-	0.04
Operating Expenses	0.43	0.63	3.22	5.4
Operating Income	-1.07	-0.63	-3.22	-5.4
Interest Expense	-0.52	-0.36	-0.45	-0.18
Currency Exchange Gain (Loss)	0.1	-	0.01	-0.11
Other Non Operating Income (Expenses)	0.63	0.58	-0.25	-1.78
EBT Excluding Unusual Items	-0.85	-0.41	-3.92	-7.47
Gain (Loss) on Sale of Investments	-0.01	-0.01	-0.02	-
Other Unusual Items	0.01	0.01	-0.35	-
Pretax Income	-1.64	-0.42	-4.29	-7.47
Net Income	-1.63	-0.42	-4.29	-7.47
Net Income to Common	-1.63	-0.42	-4.29	-7.47
Shares Outstanding (Basic)	121	133	110	53
Shares Outstanding (Diluted)	121	133	110	53
Shares Change (YoY)	-40.06%	20.80%	106.14%	-
EPS (Basic)	-0.01	-0.00	-0.04	-0.14
EPS (Diluted)	-0.01	-0.00	-0.04	-0.14
EBITDA	-	-	-	-5.36
D&A For EBITDA	-	-	-	0.04
EBIT	-1.07	-0.63	-3.22	-5.4

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.